Can-Fite stock: buy or sell?
May 22nd, 2020
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction.
Should I buy Can-Fite stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Can-Fite stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Can-Fite Biopharma stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for CANF stock for the last 30 days.
Can-Fite stock analysis
Can-Fite crossed up the simple moving average line of 200 days today and closed at $2.50, boosted a 15.21%.
Can-Fite broke up the simple moving average line of 200d today and closed at $2.50, boosted a 15.21%.
Can-Fite crossed up the simple moving average line of 200d, closing at $2.50. Early May CANF collapsed a bloodcurdling -6.36% in just one week.
Weekly chart tells us that price finally broke over the resistance at $2.39 and continued climbing.
Can-Fite stock price history
Can-Fite stock went public on October 1st, 2013 with a price of $90.001. Since then, CANF stock lost a -97.20%, with a yearly average of -16.20%.
1: Adjusted price after possible price splits or reverse-splits.
Can-Fite stock historical price chart
CANF stock reached 52-week highs on December at $4.95, and all-time highs 2013-12-23 with a price of 141.9.
Can-Fite stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price target for Can-Fite stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, when Can-Fite Biopharma published its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Can-Fite Biopharma annual sales climbed a dazzling 384.16% to $3.82 M USD from $0.79 marked in 2017. Likewise, its earnings margin (compared to revenues) skyrocketed to -172.02%, that is $-6.57 million.
|2015||$0.16 M||-||$-4.80 M-2912.3%||-|
|2016||$0.17 M||2.90%||$-6.90 M-4069.3%||43.79%|
|2017||$0.79 M||365.49%||$-6.34 M-803.4%||-8.10%|
|2018||$3.82 M||384.16%||$-6.57 M-172.0%||3.66%|
Quarterly financial resultsCan-Fite Biopharma reported $0.29 M in revenues for 2018-Q4, a -89.01% decline compared to previous quarter. Reported quarter income marked $-3.43 million with a profit margin of -1,186.51%. Profit margin plunged a -1,179.77% compared to previous quarter when profit margin was -6.73%. When comparing revenues to same quarter last year, Can-Fite sales marked an exceptional increase and rocketed a 105.33%.
|2017-Q1||$0.27 M||-||$-4.65 M-1748.1%||-|
|2017-Q2||$0.27 M||0.38%||$-7.18 M-2689.1%||54.41%|
|2017-Q3||$0.60 M||126.11%||$-0.43 M-71.6%||-93.98%|
|2017-Q4||$0.14 M||-76.69%||$-0.33 M-234.9%||-23.53%|
|2018-Q1||$0.63 M||349.04%||$-1.72 M-272.3%||420.51%|
|2018-Q2||$0.27 M||-57.28%||$-1.24 M-460.7%||-27.72%|
|2018-Q3||$2.63 M||873.70%||$-0.18 M-6.7%||-85.77%|
|2018-Q4||$0.29 M||-89.01%||$-3.43 M-1186.5%||1,837.29%|
Can-Fite ownershipReviewing Can-Fite ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Can-Fite Biopharma shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.99% of all shares.
In case of Can-Fite Biopharma stock, 9.22% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CANF stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Can-Fite:
|Market cap||$21.9 M|
|Total shares||8.8 M|
|Float shares||8.1 M|
|- Institutional holdings (%)||9.2%|
|- Insider holdings (%)||2.0%|
|Shares in short selling||0.0%|
|Friday, May 22nd, 2020|
|Day range||$2.13 - $2.59|
|Average true range||$0.21|
|50d mov avg||$1.68|
|100d mov avg||$1.88|
|200d mov avg||$2.24|
Can-Fite performanceTo better understand Can-Fite Biopharma performance you must compare its gains with other related stocks in same sector or industry. We chose as the bechmarking frame for Can-Fite stock.